RxDoctor Payments Data

Jason Cole, MD

Cardiovascular Disease · Mobile, ALNPI 1083666705

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,406 of the $8,689 with a category attached, or 73.7%. Cleerly, Inc. accounts for 74.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $6,390, more than ten times the $66 reported in 2019.

$8,689in general payments, 2019–2025

Across 36 payments — averaging $241.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$6K
  • Heartflow, Inc.$850
  • GE HealthCare$810
  • Johnson & Johnson$154
  • Esperion Therapeutics, Inc.$125
  • Boehringer Ingelheim$103
  • plus $200 from 5 others
$122,415in research payments, 2019–2025

Across 21 payments — averaging $5829.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cleerly, Inc.$100K
  • Heartflow, Inc.$22K

What the payments were for

  • Consulting fees$6,40674%
  • Travel & lodging$1,15313%
  • Food & beverage$1,13013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,689 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$1,124,471
Medicare patients
1,735
Services billed
22,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$403,008
XareltoRivaroxaban161$168,886
EntrestoSacubitril/Valsartan166$158,186
FarxigaDapagliflozin Propanediol40$26,416
Ranolazine ErRanolazine81$12,102
Repatha SureclickEvolocumab14$12,002
Atorvastatin Calcium479$6,509
Carvedilol505$4,470
Icosapent Ethyl16$4,367
Nitroglycerin99$3,583
Metoprolol Succinate217$3,289
Rosuvastatin Calcium193$2,955
ClopidogrelClopidogrel Bisulfate204$2,482
Clonidine13$2,482
SotalolSotalol Hcl64$2,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$403,008465 claims
Johnson & JohnsonXarelto$154$168,886161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →